China Approves Johnson and Johnson's Nipocalimab for Generalized Myasthenia Gravis sheeba farhat22 May 2026 10:45 PM ISTShanghai: Johnson & Johnson's nipocalimab ​treatment for ​a type of muscle-weakening disorder received ​approval from China's National Medical...
Vemircopan Fails to Demonstrate Efficacy in myasthenia gravis in Phase 2 Trial Dr. Shravani Dali5 May 2026 8:15 PM ISTIn a double-blind, placebo-controlled phase 2 randomized clinical trial, vemircopan did not meet the predefined efficacy threshold in myasthenia...
Cemdisiran Shows Efficacy for Generalized Myasthenia Gravis in Phase III Trial Medha Baranwal24 April 2026 9:00 PM ISTUSA: The investigational siRNA therapy cemdisiran met both its primary and a key secondary endpoint in the phase III NIMBLE trial for generalized...
JnJ Nipocalimab gets USFDA Priority Review designation for generalized myasthenia gravis Ruchika Sharma12 Jan 2025 3:30 PM ISTSpring House: Johnson & Johnson has announced the nipocalimab Biologics License Application (BLA) has received Priority Review designation...
New Potential treatment found for patients suffering from Myasthenia Gravis: Study Dr. Kamal Kant Kohli23 March 2024 1:30 AM ISTFor the thousands of people globally affected by the disease myasthenia gravis (MG), everyday activities become a struggle, and in severe cases, the...
Rare case of Myasthenia Gravis with Thymoma at Fortis, Vashi ft Dr Prriya Eshpuniyani Roshni Dhar19 July 2023 2:51 PM ISTAkash Ingale, was admitted to Fortis Hospital, Vashi, diagnosed with the unusual combination of Myasthenia Gravis and Thymoma. Myasthenia Gravis...
IV immunoglobulin may not help reduce corticosteroid dose among patients with myasthenia gravis Jacinthlyn Sylvia6 May 2023 8:30 AM ISTIn a new study conducted by Vera Brill, it was shown that the daily corticosteroids (CS) dose could not be decreased by caprylate/chromatography...
Patients with myasthenia gravis at High risk of Covid severity: JAMA Jacinthlyn Sylvia28 April 2023 9:00 AM ISTCompared to matched controls, persons with myasthenia gravis (MG) who caught COVID-19 had a greater risk of hospitalization and mortality, says an...
Management of Myasthenia Gravis: International Consensus Guidance Dr. Kamal Kant Kohli2 Jan 2023 9:30 AM ISTMyasthenia gravis (MG) is a chronic autoimmune disorder in which antibodies destroy the communication between nerves and muscle, resulting in weakness...
Rituximab can halt risk of deterioration in myasthenia gravis, finds JAMA study Dr. Kamal Kant Kohli25 Sept 2022 8:30 PM ISTIn myasthenia gravis, the immune system attacks the receptors between nerves and muscles, causing abnormal muscle weakness and fatigue. It often...
USFDA places clinical hold on Phase 3 Tolebrutinib studies: Sanofi Ruchika Sharma2 July 2022 12:45 PM ISTThe FDA action was based on a limited number of cases of drug-induced liver injury that have been identified with tolebrutinib exposure in Phase 3...
Ravulizumab effective treatment option for Generalized Myasthenia Gravis Dr. Shravani Dali3 Jun 2022 9:30 PM ISTRavulizumab demonstrated rapid and sustained improvements in both patient- and clinician-reported outcomes in Generalized myasthenia gravis (gMG),...
